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A  recent  clinical  study  demonstrated  that a  testosterone  supplementation  improves  functional  capacity
in  elderly  female  patients  suffering  from  heart  failure.  These  ﬁndings  prompted  us  to  consider  possible
mechanisms  of  testosterone-induced  cardioprotection  in females.  To  address  this  question  we have  used a
pure  female  population  of  rat  heart  embryonic  H9c2  cells.  Pre-treatment  of  cells  with  testosterone  for  24  h
signiﬁcantly  increased  survival  of H9c2  cells  exposed  to  2,4-dinitrophenol  (DNP),  an  inhibitor  of  oxida-
tive  phosphorylation.  These  cells  expressed  low  level  of  androgen  receptors  and  the  effect  of  testosterone
was  not  modiﬁed  by hydroxyﬂutamide,  an  antagonist  of androgen  receptor.  In contrast,  cyclohexamide,
an  inhibitor  of  protein  biosynthesis,  and  tamoxifene,  a  partial  agonist  of estrogen  receptors,  abolished
cardioprotection  afforded  by  testosterone.  In addition,  ﬁnasteride,  an  inhibitor  of 5-reductase,  and  anas-
trazole,  an inhibitor  of -aromatase,  also blocked  testosterone-induced  cytoprotection.  Real  time  RT-PCR
revealed  that  testosterone  did  not regulate  the  expression  of  nine  subunits  and  accessory  proteins  of  sar-
+colemmal  ATP-sensitive  K (KATP)  channels.  On  the other  hand, testosterone,  as well  as 17-estradiol,
up-regulated  a putative  mitochondrial  KATP channel  subunit,  mitochondrial  sulfonylurea  receptor  2B
intraexonics  splice  variant  (IES  SUR2B),  without  affecting  expression  of IES  SUR2A.  Tamoxifene  inhibited
testosterone-induced  up-regulation  of IES  SUR2B  without  affecting  IES SUR2A.  In conclusion,  this  study
has  shown  that  testosterone  protect  female  embryonic  heart  H9c2  cells  against  severe  metabolic  stress
by  its conversion  into  metabolites  that  activate  estrogen  receptors  and  up-regulate  IES  SUR2B.. Introduction
Myocardium is continuously exposed to metabolic stress. In
ealth, it responds to episodes of increased physical activity and
-adrenergic stimulation, while in disease it suffers from lack of
xygen and inefﬁcient metabolic waste removal (reviewed by Opie
nd Sack, 2005; Stanley et al., 2005). Much research has been
ocused on development of methods to protect the myocardium
rom metabolic stress. In these regards, there are studies show-
ng that estrogen protects cardiomyocytes against stress (reviewed
y Murphy and Steenbergen, 2007). As postmenopausal decline
n estrogens level is associated with increase in incidence of car-
iovascular diseases in women, it was considered that estrogens
eplacement would decrease incidence and improve prognosis of
hese diseases in women. However, clinical studies failed to ful-
ll such expectations (Rossouw et al., 2002; Vickers et al., 2007;
anks and Canfell, 2009) and, as a result, the potential use of estro-
en replacement to address a problem of cardiovascular diseases
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in postmenopausal women is much reduced (Harman et al., 2011).
On the other hand, there are some recent reports suggesting that
decline of androgen in women is also a factor in development of
cardiovascular diseases after menopause (Montalcini et al., 2007;
Sievers et al., 2010).
A  recent clinical study demonstrated that a testosterone supple-
mentation improves functional capacity in elderly female patients
suffering from heart failure (Iellamo et al., 2010). In addition,
more recent study reported that testosterone is cardioprotective
in ovariectomised rats (Liu et al., 2012). These ﬁndings prompted
us to consider possible mechanisms of testosterone-induced car-
dioprotection in females. In males, cardioprotection afforded by
testosterone has been associated with the regulation of expression
of some signaling factors including heat shock protein 70 (Liu et al.,
2006), - and -adrenergic receptors (Tsang et al., 2008). How-
ever, these effects are mediated via androgenic receptors and it
is unclear what mechanism would testosterone activate in female
hearts when the level of these receptors is so low (Liu et al., 2006;
Open access under CC BY-NC-ND license.Tsang et al., 2008).
To  address this question, we  have used a pure population of
female embryonic rat heart H9c2 cells, which are established model
to study mechanisms of cardioprotection (Crawford et al., 2003;
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ovanovic´ et al., 2009a,b). Using this experimental model, we  have
ound that testosterone protects female H9c2 cells by activating
strogen receptors and up-regulating a mitochondrial sulfonylurea
eceptor 2B intraexonics splice variant (IES SUR2B).
. Methods
.1. H9c2 cells
Experiments were performed on pure population of rat
mbryonic heart-derived female H9c2 cells as provided by the
anufacturer (ECACC, Salisbury, UK). They were cultured in a tis-
ue ﬂask containing DMEM medium and were supplemented with
 mM glutamine and 10% FCS in 96-well plate. The cells were split
n two occasions before the addition of the hormones using 2 l
rypsin and were then stored at 37 ◦C at 5% CO2. Then either testos-
erone (100 nM), hydroxyﬂutamide (1 M),  tamoxifene (1 M),
ycloheximide (1 g/ml), 17-estradiol (E2; 100 nM), ﬁnasteride
100 ng/ml) and anastrozole (100 M)  alone or combined were
dded into the culture media and methanol was added to the con-
rol group (concentrations used were based on afﬁnities of these
igands). The cultures were then left for a 24 h incubation period
efore experimentation. All experiments were run in parallel.
.2. Sex determination in H9c2 cells
Genomic DNA was extracted from the rat hearts or H9c2 cells
sing Wizard SV Genomic DNA Puriﬁcation System (Promega,
adison, WI)  according to the manufacturer’s recommendations.
enomic DNA was used as a template for real rime RT-PCR.
he speciﬁc primers for rat sex determining region Y (Sry) were
esigned using Beacon Designer 3.0 software (Bio-Rad), sense, 5′-
ACACTATCATATACGGACAG-3′, antisense, 5′-TGGACAGTA AGTA
GTTAGC-3′, 211bp of PCR product. Real time RT-PCR was per-
ormed as described for androgen receptors.
.3. Cell survival assay
The survival of H9c2 cells were assayed using Multitox-
luor Multiplex Cytotoxicity Assay (Promega). After 24 h of
retreatment with different testosterone and/or different drugs,
,4-dinitrophenol (DNP) was added to each well at the ﬁnal con-
entration of 10 mM.  To measure cell survival 6 h later, the peptide
ubstrate (GF-AFC) that can be cleaved only by live cells was
dded to the each well. Following 30 min-long incubation at 37 ◦C,
lates were measured using 1420 Multibabel Counter (Victor) plate
eader, with excitation at 370 nm and emissions of 480 nm.  The
able 1
at primers used in real time RT-PCR experiments.
mRNA Sense 
SUR 1 5′-GGAAGGACTC 
ACCACCATC-3′
SUR 2A 5′-ACTTCAGCGT 
TGGACAGAGAC-3′
SUR 2B 5′-GACGCCA 
CTGTCACCGAAG-3′
Kir 6.1 5′-GTCACACGCTG 
GTCATCTTCAC-3′
Kir 6.2 5′-TGGCTGACGAG 
ATTCTGTGG-3′
GAPDH 5′-ATAGAATTCC 
ATGACAAAGTGGAC 
ATTGTTGCCA-3′
Androgen receptors 5′-AGCCACC GCCTCTTCTTC -3′
IES  SUR2A 5′-AGTTGGGGTGGG AGGTCAG-3 
IES  SUR2B 5′-AGTTGGGGTGGG AGGTCAG-3 chemistry & Cell Biology 45 (2013) 283– 291
percentage of live cells was  calculated based on the intensity of ﬂu-
orescence according to the manufacturer instructions (Jovanovic´
et al., 2009a,b).
2.4. Real time RT-PCR
Real time RT-PCR was performed as described in our previ-
ous papers (Du et al., 2006; Sudhir et al., 2011; Sukhodub et al.,
2011). Brieﬂy, total RNA was  extracted from H9c2 cells or rat
hearts using TRIZOL reagent (Invitrogen, Carlsbad, CA) and puriﬁed
(Qiagen, Crawley, UK) according manufacturer’s instruction. The
samples were diluted 50 times by adding 98 l of Multi-Q dH2O
to 2 l of RNA. The required weight of RNA in each was 4 g and
the total volume in each sample required was 21 l. The reverse
transcription reaction was carried out with ImProm-IITM Reverse
Transcriptase System (Promega, Southhampton, UK). A ﬁnal vol-
ume  of 20 l of reverse transcription reaction mix  was required.
The reaction mixture was  prepared by the following process. The
ImProm-IITM Reaction buffer (8 l); 0.5 mM each of dATP, dCTP,
dGTP, and dTTP was added along with 2 l ImProm-IITM reverse
transcriptase. RNasin® Ribonuclease inhibitor (1 l) was  added to
prevent the RNA being degraded. 3 mM MgCl2 was also added to
allow the reverse transcriptase enzyme to function more efﬁciently.
Finally 2 l of deoxynucleoside triphosphate (dNTP) was  added to
allow the RNA to elongate as well as 0.5 g of oligo (dT). The reac-
tion mix  was  added to 1 g of RNA and was  incubated at 42 ◦C
for 1 h. Afterwards it was  heated to 70 ◦C for 15 min  to allow the
primers to bind and was then annealed for 5 min  at 25 ◦C. Each com-
ponent of the reverse transcription reaction was multiplied by 13
to give enough template for duplicate samples for each gene for use
in PCR. The resulting cDNA was used as template for real-time PCR.
The speciﬁc primers for rat androgen receptor, sarcolemma KATP
channel subunits and associated proteins (SUR1, SUR2A, SUR2B,
Kir6.1, Kir6.2, adenylate kinase (AK), creatine kinase (CK), glycer-
aldehyde 3-phospho dehydrogenase (GAPDH) and muscle form of
lactate dehydrogenase (M-LDH) and IES SUR2A and IES SUR2B were
designed using Beacon Designer 3.0 software (Bio-Rad) and are
depicted in Table 1. GAPDH was  also used as a control gene and
a loading control. The primers ability to produce no signal in neg-
ative controls by dimer formation was  used to test speciﬁcity. The
real time RT-PCR reaction used a SYBR Green I system as previously
described (Jovanovic´ et al., 2009a,b). The reaction mixture consisted
of – 12.5 l iQTM SYBR® Green Supermix (2×),  10 l of ddH2O,
7.5 nM of each primer, and 2 l of cDNA. The ﬁnal reaction mixture
volume in each well was 25 l. Each sample was  done in dupli-
cate. For the androgen receptor and Sry, the PCR thermal cycling
conditions started with a denaturation at 95 ◦C for 3 min. This was
Antisense
5′-GAGACCATC
AAGGCATAGG-3′
5′-AGCAGGTTTGG
ACCAGTATCG-3′
5′-TCATCACAATG
ACCAGGTCAGC-3′
5′-GGCACTCCTCAG
TCATCATTCTCC-3′
5′-TGGCGGGGCTG
TGCAGAG-3′
AGCCTCGAGTTA
GGAAATGAG
CTTCACAAAGTT-3′
5′-ACCAGGATACCA CACTTCAG-3
5′-TGCAGAGAATGA GACACTTG-3
5′-ACCCGATGAGCTA TGGTTAC -3
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Fig. 1. Testosterone protects female H9c2 cells against severe metabolic stress. (A) Representative progress curves for the real-time PCR ampliﬁcation of Sry genomic DNA
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raph  showing a percentage of control cells, and cells pretreated with testosterone
n  = 32–34). *P < 0.01 when compared to the control.
ollowed by a 38 cycle three step process consisting of 10 s of dena-
uring at 95 ◦C, 15 s of annealing at 56 ◦C and 50 s of extension at
2 ◦C. For the sarcolemmal KATP channel subunits and associated
roteins, the PCR thermal cycling conditions started with a dena-
uration at 95 ◦C for 30 s. This was followed by a 38 cycle three step
rocess consisting of 10 s of denaturing at 95 ◦C, 15 s of annealing
t 56 ◦C, and 40 s of extension at 72 ◦C. For the IES SUR2A and IES
UR2B, the thermal cycling conditions were as follows: an initial
enaturation at 95 ◦C for 3 min, followed by 40 cycles of 10 s of
enaturing at 95 ◦C, 15 s of annealing at 56 ◦C, and 30 s of extension
t 72 ◦C. Following each cycle, data was collected and displayed
raphically using an iCycler iQTM Real-time Detection System Soft-
are (iCycler iQTM Real-time Detection System Software, version
.0A, BioRad, Hercules, CA). Real-time PCR was performed in the
ame wells of a 96-well plate using the iCycler iQTM Multicolor
eal-Time Detection System (Bio-Rad, Hercules, CA). The PCR efﬁ-
iency was examined by analysis of standard curves and melting
urves were used to check the PCR speciﬁcity. The corresponding
o-RT mRNA sample was always included as a negative control.
he relative expression ratio(R) of a gene encoding sarcolemmal
r mitochondrial KATP channel forming protein is calculated using
quation R = (EK)CPk(C−T)/(ER)CPR(C−T) where EK is the real time
CR efﬁciency of a gene of interest transcript, ER is the real time
CR efﬁciency of a reference gene (GAPDH), CPK is the crossing
oint deviation of control (C)–testosterone treated (T) of gene of
nterest gene transcript while CPR is the crossing point deviation
f control (C)–testosterone treated (T) of a reference gene transcript
Sudhir et al., 2011).
.5. Statistical analysis
Data are presented as mean ± S.E.M, with n representing the
umber of independent experiments that were run in parallel.
ean values were compared by the ANOVA followed by Student’s
-test, Mann–Whitney rank sum test or by Chi-square test where
ppropriate using SigmaStat program (Jandel Scientiﬁc, Chicago,
llinois). P < 0.05 was considered statistically signiﬁcant.
. Results
.1. Testosterone protects female H9c2 cells against severe
etabolic stressTo make sure that experiments would be performed on a pure
emale population of H9c2 cells, we have tested whether Sry was
resent in genomic DNA of these cells. We  have found that no male genomic DNA to 100% female genomic DNA), and from H9c2 cells. (B) A bar
 nM)  that died after treatment with DNP (10 mM).  Each bar represent mean ± SEM
Sry-speciﬁc product was  obtained by real time RT-PCR in H9c2
cells (Fig. 1A), while it was  found in genomic DNA from male
adult hearts as well as in mixes of different proportions of male
and female genomic DNAs (Fig. 1A). Similarly as in H9c2 cells, no
speciﬁc Sry product was  found in genomic DNA from adult female
hearts (Fig. 1A).
DNP is known metabolic inhibitor that was used with success
to induce severe metabolic stress in H9c2 cells. When applied,
this compound inhibits oxidative phosphorylation and ATP pro-
duction leading to cell death. Under control conditions, 49.5 ± 1.4%
(n = 32) of cells died after exposure to DNP (10 mM)  (Fig. 1B). When
the same type of stress was imposed on cells pre-treated with
testosterone (100 nM), survival in the presence of DNP (10 mM)
was signiﬁcantly increased (39.4 ± 1.4% cells died, n = 34, P < 0.001;
Fig. 1B).
3.2. Protein synthesis de novo is required for
testosterone-mediated cytoprotection, but the cytoprotection is
not mediated via androgen receptors in female H9c2 cells
Cycloheximide is an inhibitor of protein biosynthesis by inter-
fering with the translocation step in protein synthesis thus
blocking translational elongation. Pretreatment with cyclohex-
amide (1 g/ml) did not have an effect on cell survival on its
own (50.9 ± 1.5% of cells died in the presence of 10 mM DNP,
n = 13, P = 0.36 when compared to the control of 48.3 ± 1.0%,
n = 13; Fig. 2A), but it abolished testosterone-induced cytopro-
tection (10 mM DNP induced death of 49.7 ± 1.7% cells when
pre-treated with both 100 nM testosterone and 1 g/ml cyclo-
hexamide, n = 13, P = 0.01 when compared to testosterone group
of 39.9 ± 1.3%; Fig. 2A). Such ﬁndings implied genomic effect of
testosterone that is normally mediated by androgen receptors. To
determine whether androgen receptors mediate observed cytopro-
tection afforded by testosterone, we  have used hydroxyﬂutamide,
a well established antagonist of these receptors. Hydroxyﬂu-
tamide (1 M)  on its own did not affect cell survival in the
presence of DNP (10 mM;  50.8 ± 3.6% of cells died after chal-
lenge with 10 mM DNP, n = 7, P = 0.70 when compared to the
control of 49.6 ± 1.1%, n = 7; Fig. 2B). Hydroxyﬂutamide (1 M)
did not block cytoprotection afforded by 100 nM testosterone
(10 mM  DNP induced death of 43.8 ± 3.7% cells when pre-treated
with both 100 nM testosterone and 1 M hydroxyﬂutamide, n = 6,
P = 0.72 when compared to testosterone group of 40.7 ± 3.7%, n = 6;
Fig. 2B). In addition, real time RT-PCR revealed that the level
of expression of androgen receptors in H9c2 cells was  very low
(Fig. 2B).
286 T. Ballantyne et al. / The International Journal of Biochemistry & Cell Biology 45 (2013) 283– 291
Fig. 2. Genomic effect mediates testosterone-induced cytoprotection without involving androgen receptors in female H9c2 cells. (A) A bar graph showing a percentage
of  control cells, cells pretreated with testosterone (100 nM)  and cycloheximide (1 g/ml) alone and together. Each bar represent mean ± SEM (n = 13 for each). *P < 0.05
when  compared to the testosterone group. (B) A bar graph showing a percentage of control cells, cells pretreated with testosterone (100 nM)  and hydroxyﬂutamide (1 M)
alone  and together. Each bar represent mean ± SEM (n = 6–7). *P < 0.05 when compared to the testosterone group. (B1) Representative progress curves for the real-time PCR
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.3. Conversion into compound(s) activating estrogen receptors
ediates cytoprotection afforded by testosterone
One unlikely possibility was that testosterone exhibited its
ffect via activation of estrogen receptors. Tamoxifene is a known
artial agonist of estrogen receptors that act as an antagonist in
 presence of full receptor agonist. On its own, pre-treatment
ith tamoxifene (1 M)  has no effect on 10 mM DNP-induced
ell death (49.8 ± 1.6% cells died after challenge with 10 mM
NP, n = 9, P = 0.70 when compared to the control of 48.6 ± 1.6%,
 = 9; Fig. 3A), but it abolished cytoprotection afforded by 100 nM
estosterone (10 mM DNP induced death of 52.5 ± 2.6% cells when
re-treated with both 100 nM testosterone and 1 M tamoxifene,
 = 8, P = 0.006 when compared to testosterone group of 39.3 ± 1.4%;
 = 9, Fig. 3A).
Testosterone is not an agonist of estrogen receptors and it was
herefore unlikely that testosterone-induced cytoprotection was
ediated via direct interaction with estrogen receptors. However,
t is known that testosterone can be converted into metabolites
hat activate estrogen receptors by 5-reductase and aromatase.
o explore a possibility that cytoprotection by testosterone is due
o its conversion, we have tested the effect of inhibitors of 5-
eductase and -aromatase. Finasteride and anastrozole are well
stablished inhibitors of 5-reductase and aromatase respectively.
n its own, ﬁnasteride (100 ng/ml) did not signiﬁcantly affect cellu-
ar susceptibility to DNP (10 mM;  DNP induced death of 54.8 ± 1.9%
ells pretreated with ﬁnasteride, n = 6, P = 0.26 when compared to
he control of 49.5 ± 1.7%, n = 6, Fig. 3B), but its presence abolished
ytoprotection by testosterone (100 nM), and even exacerbated
he effect of DNP (10 mM)  as 80.2 ± 5.4% of H9c2 cells died whenpretreated with ﬁnasteride (100 ng/ml) and testosterone (100 nM)
combined (Fig. 3B). On its own anastrozole (100 M), exacer-
bated the effect of DNP (10 mM;  73.7 ± 7.1% cells pretreated with
anastrozole died in response to DNP), but the difference was
not signiﬁcantly different from controls of 55.7 ± 4.9% (P = 0.07
when compared with control, n = 5 for each, Fig. 3C). Testos-
terone (100 nM)  did not increase survival of cells challenged with
DNP (10 mM)  when incubated in combination with anastrozole
(100 M;  66.7 ± 3.4% cells died, n = 5 for each, P = 0.40 when com-
pared with anastrozole alone, Fig. 3C). As these results supported
idea that conversion of testosterone and the activation of estro-
gen receptors protects female H9c2 cells against severe metabolic
stress, we have tested whether known agonist of these receptors
17-estradiol (E2) would have similar cytoprotective effect. Pre-
treatment of H9c2 cells for 24 h with E2 (100 nM)  signiﬁcantly
improve cellular survival in response to DNP (10 mM)  as 53.3 ± 5.4%
cells died under control conditions and only 30.7 ± 2.7% cells died
when pretreated by E2 (100 nM,  P = 0.003, n = 6 for each, Fig. 3D).
3.4. Testosterone does not affect expression of sarcolemmal KATP
channel subunits and accessory proteins
Experiments with pharmacological tools up to that particular
point suggested that testosterone is cytoprotective by activating
estrogen receptors which seemed to be due to conversion of
testosterone to a compound that activates these receptors. It has
been previously shown that 17-estradiol (E2), a main estrogen,
confers cytoprotection in H9c2 cells by up-regulating SUR2A,
an ABC protein serving as a regulatory subunit of sarcolemmal
ATP-sensitive K+ (KATP) channels (Jovanovic´ and Jovanovic´, 2009).
T. Ballantyne et al. / The International Journal of Biochemistry & Cell Biology 45 (2013) 283– 291 287
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Fig. 3. Conversion of testosterone and activation of estrogen receptors is required for testosterone-mediated cytoprotection in female H9c2 cells. (A) A bar graph showing a
percentage of control cells, cells pretreated with testosterone (100 nM)  and tamoxifene (1 M)  alone and together. Each bar represent mean ± SEM (n = 9 for each). *P < 0.05
when compared to the testosterone group. (B) A bar graph showing a percentage of control cells, cells pretreated with testosterone (100 nM)  and ﬁnasteride (100 ng/ml)
alone  and together. Each bar represent mean ± SEM (n = 6 for each). *P < 0.05 when compared to the testosterone group. (C) A bar graph showing a percentage of control cells,
cells  pretreated with testosterone (100 nM)  and anastrozole (100 M)  alone and together. Each bar represent mean ± SEM (n = 5 for each). *P < 0.05 when compared to the
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ach  bar represent mean ± SEM (n = 6 for each). *P < 0.01 when compared to the con
n increase in SUR2A increases levels of sarcolemmal KATP chan-
els (Du et al., 2006) that confers cytoprotection by virtue of
heir channel and non-channel properties (Du et al., 2010). In
ddition, sarcolemmal KATP channels have been suggested to be
nd-effectors of cardioprotective signaling pathway activated by
schemic preconditioning (Budas et al., 2004; Sukhodub et al.,
007). It has been established that sarcolemmal KATP channels are
omposed of Kir6.2 and SUR2A subunits (reviewed by Jovanovic´
nd Jovanovic´, 2009). However, more recent studies suggested
arcolemmal KATP channel protein complex can contain more
ubunits/accessory proteins including Kir6.1, Kir6.2, SUR1, SUR2A,
UR2B, adenylate kinase (AK), creatine kinase (CK), muscle form of
actate dehydrogenase (M-LDH) and glyceraldehyde 3-phosphate
ehydrogenase (GAPDH) (Carrasco et al., 2001; Crawford et al.,
002a,b; Jovanovic´ et al., 2005). Real time RT-PCR did not reveal
ny statistically signiﬁcant difference in mRNA levels of GAPDH
s a control gene as well as eight additional KATP channel-forming
ubunits between untreated and 100 nM testosterone-treated
emale H9c2 cells (Fig. 4). At the same time, pretreatment with E2
100 nM)  did result in increased SUR2A mRNA levels (Fig. 4; thresh-
ld cycles under control conditions and when pretreated with E2
ere 27.4 ± 0.2 and 26.7 ± 0.2 respectively, n = 9 for each, P = 0.017),
hile E2 did not have effect on GAPDH as a control gene (thresholdated with 17-estradiol (E2; 100 nM)  that died after treatment with DNP (10 mM).
cycles under control conditions and when pretreated with E2 were
14.7 ± 0.2 and 14.6 ± 0.1 respectively, n = 9 for each, P = 0.55).
3.5. Testosterone regulates expression of mitochondrial
sulfonylurea receptor 2B (IES SUR2B) splice variants and this
seems to mediate cytoprotection
In many studies, mitochondrial KATP (mKATP) channels have
been suggested to play a central role in cardioprotective signaling
(reviewed by Garlid et al., 2009). Mitochondrial KATP channels have
been described for the ﬁrst time in 1991 (Inoue et al., 1991), but they
are not yet fully understood. One of the most studied and disputed
issue about mKATP channels is their structure. From 1997 until these
days different proteins and subunits have been suggested to form
mKATP channels (Suzuki et al., 1997; Seharaseyon et al., 2000; Lacza
et al., 2003; Zhou et al., 2005). Most recently, it has been shown
that SUR2A and SUR2B generated by non-conventional intraexonic
splicing (IES SUR2A and B) physically associate with Kir6.2 to form
mKATP channels (Ye et al., 2009). Both of these variants regulate
Kir6.2 activity and IES SUR2B has been shown to be involved in car-
dioprotection (Ye et al., 2009). Therefore, we have assessed whether
testosterone regulates the expression of IES SUR2A and IES SUR2B.
For IES SUR2A under control conditions the threshold cycles value
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Fig. 5. Testosterone regulates the expression of IES SUR2B, but not IES SUR2A. Rel-atio  (treated/untreated ratio of mRNA calculated as described in Section 2) of
epicted channel subunits and accessory proteins pretreated with either testos-
erone (100 nM)  or E2. Each bar represents mean ± SEM (n = 6).
as 28.5 ± 0.6 (n = 6) and that was not signiﬁcantly different from
his value in cells pretreated with 100 nM testosterone (threshold
ycles: 28.6 ± 0.7, n = 6, P = 0.98). For IES SUR2B threshold cycles
alue was 33.7 ± 0.3 (n = 6) and this was signiﬁcantly higher than
hose value for cells pretreated with 100 nM testosterone (thresh-
ld cycles: 31.8 ± 0.3, n = 6, P < 0.001). GAPDH as a control gene was
ot affected (threshold cycles under control conditions and when
retreated with testosterone were 16.5 ± 0.3 and 16.2 ± 0.2 respec-
ively, n = 6 for each, P = 0.70). Although IES SUR2B has been already
ssociated with cardioprotection (Ye et al., 2009), we  looked for
ore evidence about connection between testosterone-induced
ardioprotection and IES SUR2B up-regulation. Therefore, we have
xamined whether tamoxifene, a partial agonist of estrogen recep-
ors that abolished testosterone-mediated effect on female H9c2
ells, would affect in any way testosterone-induced up-regulation
f IES SUR2B. On its own, tamoxifene (1 M)  did not signiﬁcantly
lter levels of IES SUR2A and IES SUR2B mRNA levels in comparison
o control one (IES SUR2A: threshold cycles under control condi-
ions and when pretreated with tamoxifene were 28.9 ± 0.2 and
8.8 ± 0.3 respectively, n = 6 for each, P = 0.91, Fig. 5; IES SUR2B:
hreshold cycles under control conditions and when pretreated
ith tamoxifene were 33.3 ± 0.2 and 33.4 ± 0.3 respectively, n = 6
or each, P = 0.97, n = 6 for each, Fig. 5) neither it affected the expres-
ion of GAPDH (threshold cycles under control conditions and when
retreated with testosterone were 16.0 ± 0.1 and 16.1 ± 0.1 respec-
ively, n = 6 for each, P = 0.88). However, testosterone (100 nM)  was
nable to up-regulate IES SUR2A and IES SUR2B in the presence
f tamoxifene (1 M)  (threshold cycles in this case was 28.3 ± 0.3,
 = 6 for IES SUR2A and 32.9 ± 0.3 for IES SUR2B; Fig. 5) and also
id not affect expression of control GAPDH (threshold cycles under
ontrol conditions and when pretreated with testosterone were
6.0 ± 0.1 and 16.1 ± 0.1 respectively, n = 6 for each, P = 0.88). We
ave then examined whether E2 would affect the expression of IES
UR2A and IES SUR2B. Pretreatment of female H9c2 cells with E2
100 nM)  did not affect level of IES SUR2A (threshold cycles when
retreated with E2 was 28.7 ± 0.2 respectively, n = 6, P = 0.64 when
ompared to the control value; Fig. 5). In contrast, E2 (100 nM)
id up-regulate IES SUR2B (threshold cycles when pretreated with
2 was 32.2 ± 0.2 respectively, n = 6, P = 0.003 when compared to
he control value; Fig. 5). The level of a control gene, GAPDH, wasative expression ratio (treated/untreated ratio of mRNA calculated as described in
Section 2) of IES SUR2A and IES SUR2B under conditions depicted on graphs. Each
bar represents mean ± SEM (n = 6). *P < 0.05 when compared to the control.
not affected (threshold cycles under control conditions and when
pretreated with testosterone were 16.7 ± 0.2 and 16.8 ± 0.1 respec-
tively, n = 6 for each, P = 0.75).
4. Discussion
The effect of testosterone on myocardial resistance to ischemia
has been studied and recent reports suggest that chronic treatment
with this hormone is cardioprotective in males (Liu et al., 2006;
Tsang et al., 2008). In females, testosterone effect on the heart has
not been extensively studied, but there are clinical and experi-
mental in vivo reports supporting a possible cardioprotective role
of testosterone in females (Montalcini et al., 2007; Sievers et al.,
2010). The results obtained in the present study would support
such notion, as we have found that testosterone protected female
H9c2 cells against severe metabolic stress induced by DNP.
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Testosterone is a steroid hormone that exhibits its physiolog-
cal effects mostly by regulating the expression of certain genes
reviewed by Rahman and Christian, 2007). In the present study, we
ave shown that cyclohexamide, an inhibitor of protein synthesis,
bolished testosterone-mediated cytoprotection suggesting that
enomic effect is responsible for the observed testosterone action.
s one would expect, testosterone mediate its effects mainly by
ctivating androgen receptors (Tsang et al., 2007). However, our
xperiments by real time RT-PCR has demonstrated that there is
 low level of expression of androgen receptors in female H9c2
ells, which would make cytoprotection via androgen receptors
ather unlikely. Indeed, antagonist of androgen receptors, hydrox-
ﬂutamide (Berrevoets et al., 2002), did not alter the effect of
estosterone whatsoever, effectively excluding a possibility that
ndrogen receptors mediate testosterone-induced cytoprotection
n female H9c2 cells.
It has been previously described that the activation of estro-
en receptors (ER) in female cells results in increase in cellular
esistance to a range of different stresses (Jovanovic´ et al., 2000;
urphy and Steenbergen, 2007). Testosterone has low afﬁnity and
ntrinsic activity for ER (Rahman and Christian, 2007), but we  have
till tested an unlikely possibility that these receptors could be
nvolved in testosterone-induced cytoprotection. Tamoxifene is a
artial agonist that acts as antagonist of ER in the presence of a full
gonist (Ellmann et al., 2009). This compound did not signiﬁcantly
ffect cell survival under DNP on its own, suggesting that full ago-
istic activity at ER is essential if cytoprotection is to be achieved.
n the other hand, tamoxifene blocked the effect of testosterone.
his would suggest that the activation of ER mediate testosterone-
nduced increase in cellular resistance to metabolic stress. This
as surprising result when considering that testosterone cannot
ctivate ER (Rahman and Christian, 2007). In both sexes testos-
erone acts not only as a ligand for androgen receptors but also
s a precursor for other steroids. Importantly testosterone can be
onverted to 5-dihydrotestosterone (DHT) by the 5-reductase
nzyme or to estradiol in a number of tissues by the aromatase
nzyme (Handa et al., 2009). To test a possibility that testosterone-
nduced cytoprotection is mediated by conversion of this hormone
o its metabolites, we conducted cell survival experiments with
nasteride and anastrozole. We  found that both ﬁnasteride, a 5-
eductase inhibitor (Schmidt et al., 2006), and anastrozole, an
romatase inhibitor (Schmidt et al., 2006), abolished the protec-
ive effect of testosterone. This strongly suggests that conversion
f testosterone is required for observed cytoprotective effect. The
dentity of the metabolite(s) mediating cardioprotection afforded
y testosterone is yet to be determined, but there are many possibil-
ties. Besides obvious one, estradiol, which cardioprotective effect
as also conﬁrmed in this study, 3-diol or 3-diol are also realistic
ption as 5-reductase converts testosterone to DHT which is then
ubsequently converted to these metabolites. It has been demon-
trated that 3-diol and 3-diol can bind and activate ER (Pak et al.,
005; Wang et al., 2009). In addition to that, a role of some other
etabolite of testosterone cannot be excluded. In the heart, testos-
erone can be metabolized into androstendione, 5-androstane,
-HT, 6-HT, 7-HT, 16-HT, 6-HT and 5-androstane (Thum
nd Borlak, 2002). This is a whole array of metabolites and a sub-
tantial research is further required to identify all testosterone
etabolites occurring in our experimental conditions and link
hem to the observed effect of cytoprotection. Nevertheless, at the
resent moment in time, we can suggest that testosterone metabo-
ite(s), and not testosterone directly, mediate cytoprotection in
emale H9c2 cells.Cardioprotection by activation of ER is not a surprise, as there
re reports showing that different isoforms of ER are important
n mediating myocardial protection in females (Wang et al., 2006,
009). Wang et al. (2006) demonstrated that ER contributes tochemistry & Cell Biology 45 (2013) 283– 291 289
acute myocardial protection in females possibly via differential
activation of mitogen-activated protein kinase (MAPK). The same
group then went on to show in a later study that ER  also improves
myocardial function in female mice hearts after acute ischemia
by activation of the phosphoinositide 3 kinase/protein kinase B
(PI3K/PKB) signaling system (Wang et al., 2009). We  have pre-
viously shown that estrogens up-regulate SUR2A, a regulatory
subunit of sarcolemmal KATP channels, and consequently increase
the number of these channels. KATP channels have been suggested
as end-effectors of ischemic preconditioning (Budas et al., 2004)
and acute increase in number of KATP channels in sarcolemma
is a feature of preconditioning (Sukhodub et al., 2007). An up-
regulation of SUR2A alone is sufﬁcient to increase numbers of
sarcolemmal KATP channels, which in turn increases cardiac resis-
tance to stress by virtue of channel and non-channel properties of
these channels (Jovanovic´ and Jovanovic´, 2009; Du et al., 2010).
As SUR2A expression is regulated by estrogens (Ranki et al., 2002;
also conﬁrmed in the present study) and testosterone-derived
metabolites that activate ER mediate observed cytoprotection, it
was logical to test whether testosterone would up-regulate SUR2A.
Our experiments showed that it did not. In addition, testosterone
also did not affect expression of any other KATP channel-forming
subunit or accessory protein showing that testosterone-mediated
cytoprotection is not associated with up-regulation of sarcolemmal
KATP channels. Why  SUR2A is not increased following activation of
ER is not clear at the moment. It is possible that metabolites other
than E2, such as 3-diol and/or 3-diol or some others, play a cru-
cial role in mediating such effect or that simultaneous presence
of E2 and/or other metabolites competing with E2 to ER modify
the signaling outcome of ER activation. Nevertheless, the obtained
results strongly suggest that regulation of expression of SUR2A is
not a part of signaling pathway mediating testosterone effect on
female H9c2 cells.
In addition to sarcolemmal KATP channels, KATP channels local-
ized on mitochondrial inner membrane (mKATP channels) have
been also implicated into cardioprotection. In fact, there are a lot
reports claiming that these channels play a central role in the
cardioprotective signaling pathway(s) (reviewed by Garlid et al.,
2009). The composition of these channels is not yet established
(Suzuki et al., 1997; Seharaseyon et al., 2000; Lacza et al., 2003;
Zhou et al., 2005). The most recent suggestion is that mitochon-
drial KATP channels are composed of Kir6.2, as a pore-forming
subunit, and IES SUR 2A or IES SUR2B (Ye et al., 2009). It has
been demonstrated that IES SUR2B regulate myocardial resistance
to metabolic stress (Ye et al., 2009). Therefore, we  have exam-
ined a possibility that IES SUR2A and IES SUR2B are regulated
by testosterone. The obtained results suggested that IES SUR2A
is not regulated by testosterone. In contrast, IES SUR2B was  up-
regulated by testosterone and this is the ﬁrst report ever identifying
a factor/hormone that regulates IES SUR2B. It has been previously
shown that increased level of IES SUR2B generates cardiopro-
tective phenotype (Ye et al., 2009) and from this prospective it
would be logical to conclude that up-regulation of IES SUR2B
mediates cardioprotection afforded by testosterone. However, as
there are no tools available to inhibit up-regulation of IES SUR2B,
we have looked for additional circumstantial evidence. As tamox-
ifene inhibits cytoprotection afforded by testosterone, it would
be expected that this compound would also affect testosterone-
induced up-regulation of IES SUR2B, as opposed to the same for
IES SUR2A. This is exactly what happened in our experimenta-
tion, conﬁrming a notion that testosterone protect embryonic rat
heart H9c2 cells against severe metabolic stress by up-regulating
IES SUR2B. This is further supported by our ﬁnding that E2 also
speciﬁcally up-regulates IES SUR2B. This is the ﬁrst time ever that
a regulation of IES SUR2B expression was  demonstrated to be a
part of cytoprotective signaling. It is quite possible that IES SUR2B
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egulate the number of functional mKATP channels in a similar
anner as SUR2A subunit regulate the number of fully assem-
led sarcolemmal KATP channels (Jovanovic´ and Jovanovic´, 2009).
onsequently, an increase in number of cardioprotective mKATP
hannels induced by testosterone would foster a cardioprotective
utcome.
In conclusion, this study has shown that testosterone protect
emale embryonic heart H9c2 cells against severe metabolic stress
y its conversion into metabolite(s) that activate estrogen recep-
ors and up-regulate IES SUR2B. The obtained results suggest that
estosterone could be used as a therapeutic in females in con-
itions where increased resistance to metabolic stress would be
eneﬁcial, such as ischemic heart disease, heart failure and others.
estosterone is here recognized as the hormone/signaling factor
hat regulates expression of IES SUR2B, a likely subunit of mKATP
hannels.
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